Search Details

Word: pharma (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...really prevent pregnancy? The U.S. needs to keep up with the burgeoning Third World anyway. And even though most respondents would rather that several (million?) of their best buddies be immersed in water, they clearly prefer Coca-Cola’s secret formula to nonoxynol-9. Sorry, big pharma; congrats, big sugar...

Author: By Joseph P. Shivers, CONTRIBUTING WRITER | Title: Coke (Coca-Cola) Kills (Sperm) | 10/15/2008 | See Source »

...company's bid to control biotech superstar Genentech. Together, the two strategies form the nucleus of how Roche plans to deliver best-in-class products--faster, more cheaply and more reliably--to market. "The days of an attrition-based pipeline are over," says Lee Babiss, head of global pharma research. "We've responded by making R&D much more efficient...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

...many ways, Big Pharma can't afford not to. Getting drugs to the market has never been more expensive. The price tag for developing a single medication can now top $1 billion, compared with less than $300 million 15 years ago. That rise is due, in large part, to a growing need to produce bigger and bolder breakthroughs as portfolios mature and patents lapse. The market wants fewer "me too" products, instead demanding originality. And drugmakers are working overtime to distinguish themselves: in 2006 the top seven pharmaceutical companies spent twice as much on marketing...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

British forecaster EvaluatePharma says Roche is on track to take over as Big Pharma's top dog by 2014, up from No. 5 today. But it won't get there without a fight. Crosstown rival Novartis is also revamping how it does R&D and holds a 13% stake in Alnylam. U.K. concern GlaxoSmithKline already underwent its own re-engineering, and the results are evident. In 2000 its pipeline had two major prospects; now, stocked with 34 late-phase drugs on the horizon, it appears to be one of the industry's healthiest...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

...globally in sales nearly 25%, to $4.1 billion, last year. "You need self-confidence to take risks," Schwan says. But, he adds, "if you are successful, you must be even more thoughtful about the future rather than dwelling on the past." And that prescription may be just what Big Pharma needs...

Author: /time Magazine | Title: Roche's Rush | 10/2/2008 | See Source »

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next